Trends, predictors, and impact of systemic chemotherapy in small cell lung cancer patients between 1985 and 2005

Madhusmita Behera, Camille Ragin, Sungjin Kim, Rathi N. Pillai, Zhengjia Chen, Conor E. Steuer, Nabil F. Saba, Chandra P. Belani, Fadlo R. Khuri, Suresh S. Ramalingam, Taofeek K. Owonikoko

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

BACKGROUND The last 3 decades have witnessed limited therapeutic advances in small cell lung cancer (SCLC) management. This study evaluated real-world trends in the use of systemic therapies and the impact on patient outcomes in the United States. METHODS The Surveillance, Epidemiology, and End Results-Medicare database was used to find patients diagnosed with SCLC between 1985 and 2005. The 1985-1990 period served as the baseline for a temporal analysis conducted at 5-year intervals (1985-1990, 1991-1995, 1996-2000, and 2001-2005). Cox proportional models were used to estimate the effect of chemotherapy on survival. Results were validated with a propensity-matched analysis. RESULTS There were 47,351 eligible patients: 52% were male; the median age was 71 years; and 87% were white, 7% were black, and 1.4% were Asian. The proportion of patients treated with chemotherapy was low but increased over time (38%, 55%, 50%, and 53%; P <.001). Race, diagnosis period, age, stage, and location of residence significantly predicted chemotherapy use. Females (51%), Asians (53%), and rural residents (60%) were more likely to receive chemotherapy. The median overall survival with and without chemotherapy was 9.6 and 3.6 months, respectively. Linear trend analyses showed a modest reduction in the impact of chemotherapy on survival for patients treated with chemotherapy versus untreated patients (hazard ratios [HRs], 0.59, 0.61, 0.64, and 0.62; P <.001) but an overall trend of improved survival for treated (HRs, 1.0, 1.03, 1.00, and 0.96; P =.005) and untreated patients (HRs, 1.0, 0.99, 0.94, and 0.92; P <.001). There was no survival difference between patients treated with carboplatin and patients treated with cisplatin (HR, 0.99; confidence interval [CI], 0.81-1.19; P =.875). Additional therapy beyond platinum-based chemotherapy was associated with a survival benefit (HR, 0.78; CI, 0.75-0.81; P <.001). CONCLUSIONS Chemotherapy use was associated with a survival benefit in Medicare patients with SCLC treated in a real-world setting. Cancer 2016;122:50-60. This study evaluates real-world trends in the use of systemic therapies and the impact on patient outcomes in the United States. Chemotherapy use is associated with a survival benefit in US Medicare-eligible patients with small cell lung cancer treated in a real-world setting.

Original languageEnglish (US)
Pages (from-to)50-60
Number of pages11
JournalCancer
Volume122
Issue number1
DOIs
StatePublished - Jan 1 2016

Fingerprint

Small Cell Lung Carcinoma
Drug Therapy
Survival
Medicare
Confidence Intervals
Carboplatin
Therapeutics
Platinum
Proportional Hazards Models
Cisplatin
Epidemiology
Databases

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Behera, M., Ragin, C., Kim, S., Pillai, R. N., Chen, Z., Steuer, C. E., ... Owonikoko, T. K. (2016). Trends, predictors, and impact of systemic chemotherapy in small cell lung cancer patients between 1985 and 2005. Cancer, 122(1), 50-60. https://doi.org/10.1002/cncr.29674
Behera, Madhusmita ; Ragin, Camille ; Kim, Sungjin ; Pillai, Rathi N. ; Chen, Zhengjia ; Steuer, Conor E. ; Saba, Nabil F. ; Belani, Chandra P. ; Khuri, Fadlo R. ; Ramalingam, Suresh S. ; Owonikoko, Taofeek K. / Trends, predictors, and impact of systemic chemotherapy in small cell lung cancer patients between 1985 and 2005. In: Cancer. 2016 ; Vol. 122, No. 1. pp. 50-60.
@article{31b5024ae0a340b0b966ad6d44fa1979,
title = "Trends, predictors, and impact of systemic chemotherapy in small cell lung cancer patients between 1985 and 2005",
abstract = "BACKGROUND The last 3 decades have witnessed limited therapeutic advances in small cell lung cancer (SCLC) management. This study evaluated real-world trends in the use of systemic therapies and the impact on patient outcomes in the United States. METHODS The Surveillance, Epidemiology, and End Results-Medicare database was used to find patients diagnosed with SCLC between 1985 and 2005. The 1985-1990 period served as the baseline for a temporal analysis conducted at 5-year intervals (1985-1990, 1991-1995, 1996-2000, and 2001-2005). Cox proportional models were used to estimate the effect of chemotherapy on survival. Results were validated with a propensity-matched analysis. RESULTS There were 47,351 eligible patients: 52{\%} were male; the median age was 71 years; and 87{\%} were white, 7{\%} were black, and 1.4{\%} were Asian. The proportion of patients treated with chemotherapy was low but increased over time (38{\%}, 55{\%}, 50{\%}, and 53{\%}; P <.001). Race, diagnosis period, age, stage, and location of residence significantly predicted chemotherapy use. Females (51{\%}), Asians (53{\%}), and rural residents (60{\%}) were more likely to receive chemotherapy. The median overall survival with and without chemotherapy was 9.6 and 3.6 months, respectively. Linear trend analyses showed a modest reduction in the impact of chemotherapy on survival for patients treated with chemotherapy versus untreated patients (hazard ratios [HRs], 0.59, 0.61, 0.64, and 0.62; P <.001) but an overall trend of improved survival for treated (HRs, 1.0, 1.03, 1.00, and 0.96; P =.005) and untreated patients (HRs, 1.0, 0.99, 0.94, and 0.92; P <.001). There was no survival difference between patients treated with carboplatin and patients treated with cisplatin (HR, 0.99; confidence interval [CI], 0.81-1.19; P =.875). Additional therapy beyond platinum-based chemotherapy was associated with a survival benefit (HR, 0.78; CI, 0.75-0.81; P <.001). CONCLUSIONS Chemotherapy use was associated with a survival benefit in Medicare patients with SCLC treated in a real-world setting. Cancer 2016;122:50-60. This study evaluates real-world trends in the use of systemic therapies and the impact on patient outcomes in the United States. Chemotherapy use is associated with a survival benefit in US Medicare-eligible patients with small cell lung cancer treated in a real-world setting.",
author = "Madhusmita Behera and Camille Ragin and Sungjin Kim and Pillai, {Rathi N.} and Zhengjia Chen and Steuer, {Conor E.} and Saba, {Nabil F.} and Belani, {Chandra P.} and Khuri, {Fadlo R.} and Ramalingam, {Suresh S.} and Owonikoko, {Taofeek K.}",
year = "2016",
month = "1",
day = "1",
doi = "10.1002/cncr.29674",
language = "English (US)",
volume = "122",
pages = "50--60",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

Behera, M, Ragin, C, Kim, S, Pillai, RN, Chen, Z, Steuer, CE, Saba, NF, Belani, CP, Khuri, FR, Ramalingam, SS & Owonikoko, TK 2016, 'Trends, predictors, and impact of systemic chemotherapy in small cell lung cancer patients between 1985 and 2005', Cancer, vol. 122, no. 1, pp. 50-60. https://doi.org/10.1002/cncr.29674

Trends, predictors, and impact of systemic chemotherapy in small cell lung cancer patients between 1985 and 2005. / Behera, Madhusmita; Ragin, Camille; Kim, Sungjin; Pillai, Rathi N.; Chen, Zhengjia; Steuer, Conor E.; Saba, Nabil F.; Belani, Chandra P.; Khuri, Fadlo R.; Ramalingam, Suresh S.; Owonikoko, Taofeek K.

In: Cancer, Vol. 122, No. 1, 01.01.2016, p. 50-60.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Trends, predictors, and impact of systemic chemotherapy in small cell lung cancer patients between 1985 and 2005

AU - Behera, Madhusmita

AU - Ragin, Camille

AU - Kim, Sungjin

AU - Pillai, Rathi N.

AU - Chen, Zhengjia

AU - Steuer, Conor E.

AU - Saba, Nabil F.

AU - Belani, Chandra P.

AU - Khuri, Fadlo R.

AU - Ramalingam, Suresh S.

AU - Owonikoko, Taofeek K.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - BACKGROUND The last 3 decades have witnessed limited therapeutic advances in small cell lung cancer (SCLC) management. This study evaluated real-world trends in the use of systemic therapies and the impact on patient outcomes in the United States. METHODS The Surveillance, Epidemiology, and End Results-Medicare database was used to find patients diagnosed with SCLC between 1985 and 2005. The 1985-1990 period served as the baseline for a temporal analysis conducted at 5-year intervals (1985-1990, 1991-1995, 1996-2000, and 2001-2005). Cox proportional models were used to estimate the effect of chemotherapy on survival. Results were validated with a propensity-matched analysis. RESULTS There were 47,351 eligible patients: 52% were male; the median age was 71 years; and 87% were white, 7% were black, and 1.4% were Asian. The proportion of patients treated with chemotherapy was low but increased over time (38%, 55%, 50%, and 53%; P <.001). Race, diagnosis period, age, stage, and location of residence significantly predicted chemotherapy use. Females (51%), Asians (53%), and rural residents (60%) were more likely to receive chemotherapy. The median overall survival with and without chemotherapy was 9.6 and 3.6 months, respectively. Linear trend analyses showed a modest reduction in the impact of chemotherapy on survival for patients treated with chemotherapy versus untreated patients (hazard ratios [HRs], 0.59, 0.61, 0.64, and 0.62; P <.001) but an overall trend of improved survival for treated (HRs, 1.0, 1.03, 1.00, and 0.96; P =.005) and untreated patients (HRs, 1.0, 0.99, 0.94, and 0.92; P <.001). There was no survival difference between patients treated with carboplatin and patients treated with cisplatin (HR, 0.99; confidence interval [CI], 0.81-1.19; P =.875). Additional therapy beyond platinum-based chemotherapy was associated with a survival benefit (HR, 0.78; CI, 0.75-0.81; P <.001). CONCLUSIONS Chemotherapy use was associated with a survival benefit in Medicare patients with SCLC treated in a real-world setting. Cancer 2016;122:50-60. This study evaluates real-world trends in the use of systemic therapies and the impact on patient outcomes in the United States. Chemotherapy use is associated with a survival benefit in US Medicare-eligible patients with small cell lung cancer treated in a real-world setting.

AB - BACKGROUND The last 3 decades have witnessed limited therapeutic advances in small cell lung cancer (SCLC) management. This study evaluated real-world trends in the use of systemic therapies and the impact on patient outcomes in the United States. METHODS The Surveillance, Epidemiology, and End Results-Medicare database was used to find patients diagnosed with SCLC between 1985 and 2005. The 1985-1990 period served as the baseline for a temporal analysis conducted at 5-year intervals (1985-1990, 1991-1995, 1996-2000, and 2001-2005). Cox proportional models were used to estimate the effect of chemotherapy on survival. Results were validated with a propensity-matched analysis. RESULTS There were 47,351 eligible patients: 52% were male; the median age was 71 years; and 87% were white, 7% were black, and 1.4% were Asian. The proportion of patients treated with chemotherapy was low but increased over time (38%, 55%, 50%, and 53%; P <.001). Race, diagnosis period, age, stage, and location of residence significantly predicted chemotherapy use. Females (51%), Asians (53%), and rural residents (60%) were more likely to receive chemotherapy. The median overall survival with and without chemotherapy was 9.6 and 3.6 months, respectively. Linear trend analyses showed a modest reduction in the impact of chemotherapy on survival for patients treated with chemotherapy versus untreated patients (hazard ratios [HRs], 0.59, 0.61, 0.64, and 0.62; P <.001) but an overall trend of improved survival for treated (HRs, 1.0, 1.03, 1.00, and 0.96; P =.005) and untreated patients (HRs, 1.0, 0.99, 0.94, and 0.92; P <.001). There was no survival difference between patients treated with carboplatin and patients treated with cisplatin (HR, 0.99; confidence interval [CI], 0.81-1.19; P =.875). Additional therapy beyond platinum-based chemotherapy was associated with a survival benefit (HR, 0.78; CI, 0.75-0.81; P <.001). CONCLUSIONS Chemotherapy use was associated with a survival benefit in Medicare patients with SCLC treated in a real-world setting. Cancer 2016;122:50-60. This study evaluates real-world trends in the use of systemic therapies and the impact on patient outcomes in the United States. Chemotherapy use is associated with a survival benefit in US Medicare-eligible patients with small cell lung cancer treated in a real-world setting.

UR - http://www.scopus.com/inward/record.url?scp=84947998924&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947998924&partnerID=8YFLogxK

U2 - 10.1002/cncr.29674

DO - 10.1002/cncr.29674

M3 - Article

C2 - 26441041

AN - SCOPUS:84947998924

VL - 122

SP - 50

EP - 60

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 1

ER -